%0 Journal Article
%T Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing
%A Alexandra Traverse-Glehen
%A Ana£¿s Pujals
%A Anissa Moktefi
%A Aur¨¦lie Dupuy
%A Christiane Copie-Bergman
%A Corinne Haioun
%A Cyrielle Robe
%A Elsa Poullot
%A Fran£¿ois Lemonnier
%A Karima Mokhtari
%A Laurence de Leval
%A Marie C. Rousselet
%A Marie H. Delfau-Larue
%A Nadine Martin-Garcia
%A Nicolas Ortonne
%A Olivier Tournilhac
%A Philippe Gaulard
%A Richard Delarue
%A Romain Pelletier
%A Virginie Fataccioli
%J The Journal of Molecular Diagnostics
%D 2018
%R 10.1016/j.jmoldx.2018.05.012
%X Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma associated
with chemoresistance and a poor prognosis. Various nonsynonymous mutations in the
R172 residue of IDH2 are present in 20% to 30% of AITL patients. In addition to their
diagnostic value, these mutations are potentially targetable, especially by isocitrate
dehydrogenase (IDH) 2 inhibitor, and therefore their identification in a routine setting
is clinically relevant. However, in AITL, the neoplastic cells may be scarce, making
the identification of molecular anomalies difficult.
%U https://jmd.amjpathol.org/article/S1525-1578(17)30535-4/fulltext